ArticleInfluenza and other respiratory viruses2026
A Monoclonal Antibody ELISA-Based Assay for Measuring the Potency of Candidate H5 Clade 2.3.4.4b Pandemic Influenza Vaccines.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe single radial immunodiffusion (SRID) assay is used to determine the potency of inactivated influenza vaccines. Nevertheless, development of alternative influenza vaccine potency assays with greater sensitivity and less reliance on large quantities of reference reagents is needed. Many candidate alternative potency assays use monoclonal antibodies (mAbs) to quantify the relevant immunogenic form of HA in vaccines. Although the feasibility of such assays has been demonstrated, concerns remain as to whether the necessary antibody reagents can be generated in the timeframes of vaccine manufacture, particularly for pandemic vaccines.
methodsWe describe the development and evaluation of a mAb-based ELISA assay to measure the potency of several candidate H5 clade 2.3.4.4b A/Astrakhan/3212/2020 influenza vaccines prepared recently in response to the ongoing H5N1 outbreak in the United States. The assay uses H5 mAbs that were generated and characterized several years prior to the emergence of these H5N1 viruses.
resultsCorrelation of the ELISA potency results with traditional SRID potency values was excellent for a cell-based vaccine and one egg-based vaccine. The ELISA and SRID potency values for the second egg-based vaccine were not as well aligned initially, but alignment was improved by use of an internal standard.
conclusionsThe results demonstrated that the ELISA potency assay is suitable for determining the potency of inactivated H5 A/Astrakhan/3212/2020 influenza vaccines. Moreover, the results demonstrate the importance of preparing libraries of antibody reagents for influenza subtypes with pandemic potential so that suitable mAbs are available for development of alternative mAb vaccine potency assays when needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.